GS
EDIT icon

GTS Securities’s Editas Medicine EDIT Stock Holding History

GTS Securities’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,400
Closed -$71.9K – 4146
2024
Q2 		$71.9K Sell
15,400
-5,700
-27% -$32.2K ﹤0.01% 3673
2024
Q1 		$157K Buy
21,100
+200
+1% +$1.66K ﹤0.01% 3421
2023
Q4 		$212K Sell
20,900
-25,900
-55% -$227K ﹤0.01% 3519
2023
Q3 		$365K Buy
+46,800
New +$401K ﹤0.01% 2896

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GTS Securities's EDIT Position: Q4 2024 in Review

GTS Securities sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 11,151 shares — an estimated $38K sold.

GTS Securities first reported a position in EDIT in Q2 2023 and held it in 6 quarters. The position peaked at $517K in Q4 2023. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

  • GTS Securities reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 11,151 Editas Medicine shares in Q4 2024, an estimated $38K.
  • GTS Securities first reported a position in Editas Medicine in Q2 2023 and held it in 6 quarters.
  • GTS Securities's Editas Medicine position peaked at $517K in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.